Entera Bio Ltd. develops orally delivered peptide and protein replacement therapies as a clinical-stage biopharmaceutical company. News about ENTX centers on its N-Tab® oral peptide platform and pipeline candidates, including EB613, an oral PTH(1-34) tablet for osteoporosis, and EB612, a long-acting oral PTH peptide replacement tablet for hypoparathyroidism.
Recurring updates also cover FDA communications and clinical-development plans, OPKO collaboration activity, financial results, private placements and warrant-linked capital actions, board and governance changes, and medical-community discussions around osteoporosis and oral anabolic therapy.
Entera Bio Ltd. (NASDAQ: ENTX) announced its participation in the BTIG Biotechnology Conference on August 10, 2020, at 12:30 p.m. EDT. The event will be available via a live webcast on the company's Investor Relations page. A replay will be accessible for 45 days post-presentation.
Entera specializes in orally delivered macromolecule therapeutics addressing significant medical needs, particularly for patients who struggle with injectable therapies. Their leading candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 clinical development.
Summary not available.
Entera Bio Ltd. (NASDAQ: ENTX) reported significant progress in its Phase 2 clinical trial of EB613 for osteoporosis, with interim data showing statistically significant increases in the P1NP biomarker after one month of treatment. The 1.5 mg dose demonstrated notable improvement over placebo. The company plans to follow patients for six months to analyze bone mineral density data and explore higher doses for potential Phase 3 trials. Financially, Entera reported Q1 2020 revenue of $42,000 with a net loss of $(2.9) million, and cash reserves of $13.3 million, projected to last until mid-2021.
Entera Bio Ltd. (NASDAQ: ENTX) has announced it will release interim biomarker data from its Phase 2 osteoporosis clinical trial of EB613 and financial results for Q1 2020 on May 21, 2020, before the market opens. The first half of data will cover 50% of enrolled patients. A conference call will be held on the same day at 8:30 a.m. EDT to discuss findings and results, with a Q&A session to follow. Entera Bio focuses on developing orally delivered large molecule therapeutics, addressing unmet medical needs.